$萬春醫藥 (BYSI.US)$ Brothers and Sisters, let's not be discouraged right now, read up CCXI May 7 when they FDA got rejected too,share plummeted 59%.but they appeal,they resubmit mire datas, they got it approved in october.
Let's just wait for the news release from company, i think the docs n researchers are not so dumb to submit something that will deemed failure to FDA. They worked years on plinabulin just like CCXI on their Avacopan.
Let's just wait for the news release from company, i think the docs n researchers are not so dumb to submit something that will deemed failure to FDA. They worked years on plinabulin just like CCXI on their Avacopan.
6
3
$萬春醫藥 (BYSI.US)$
please let there be some good news in 2022
please let there be some good news in 2022
4
$ChemoCentryx (CCXI.US)$
$蔚來 (NIO.US)$
$Meta Platforms (FB.US)$
$Altimeter Growth Corp (AGC.US)$
$美國超微公司 (AMD.US)$
有人能告訴我剛剛發生了什麼,同樣的趨勢突然都下降了.. 我所有的綠色都變成紅色的海
$蔚來 (NIO.US)$
$Meta Platforms (FB.US)$
$Altimeter Growth Corp (AGC.US)$
$美國超微公司 (AMD.US)$
有人能告訴我剛剛發生了什麼,同樣的趨勢突然都下降了.. 我所有的綠色都變成紅色的海
已翻譯
47
18
23
5
3
1
已翻譯
2
2
Butterfly_Effect 樓主 : 我知道 CRL 和延長(CCXI)是不同的事情,但我也讀到 CRL 允許上訴。最壞情況 BYSI 沒有提出上訴,但他們在其製程中獲得了 FDA 中國批准,並且對 NSCLC 和其他藥物進行了第三句,因此他們的 CIN 上的 CRL 毫無疑問是破壞的,但它不應該是 BYSI 的死刑。這只是我對此而言只是我的責任我也被困在 13.80 的位置,而且數量子彈的平均值下降。